Abstract Details

Title Investigational Study on the Degree of Contrast Sensitivity Visual Acuity Defects in Early Stages of Parkinsonism

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) P06 - (-)

Poster/Presentation
Number 001

Objective

Background BACKGROUND: Deficiencies in contrast sensitivity visual acuity are recognized in patients with Parkinson's disease, presumably due to loss of retinal dopamine. However, to date no study has detailed the presence or degree of loss correlated with the stages of Parkinsonism.

Design/Methods DESIGN/METHODS: 25 early-stage Parkinson's subjects Stage I-II H&Y (12 stage I, 3 stage I/II, 10 stage II) versus 25 controls were studied. Participants completed questionnaires about their vision, eye pathology, current medications, and four symptoms typically seen in premotoric state of Parkinson's. Tests included UPDRS, directive and contrast sensitivity visual acuities (SLOAN) at 100%, 2.5%, and 1.25%, intraocular pressure, Schirmer's test for tear film formation, Farnsworth 100 and HRR color vision tests, confrontational visual fields, extraocular movements, pupillary functions, dilated funduscopic exam, and Spectral Optical Coherence Tomography (OCT) to quantitatively assess inner retinal layers. Visual acuity <20/50 and known co-morbid ophthalmologic pathologies were exclusionary. The statistical methods used were the student's t-test and analysis of variance.

Results RESULTS: Univariate analysis demonstrates a high statistical difference between patients with early PD and controls. PD patients showed statistically poorer contrast acuity at 2.5% and 1.25% visual performance (P<0.05). Further multivariate analysis comparing the relative frequency of contrast sensitivity defects against what are acknowledged premotoric symptoms will be discussed.

Conclusions CONCLUSIONS: In early PD patients with normal directive visual acuity, we found significantly decreased contrast sensitivity visual acuity. Contrast sensitivity testing in the office setting (SLOAN Wall Chart) can objectively detect early subclinical PD-related visual impairment.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Megan Walley, MD (Ohio Health Physicians Group)	No disclosure on file
	No disclosure on file
Charles Maitland	No disclosure on file
Florian Deisenhammer, MD	Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS/Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall. Dr. Deisenhammer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SOBI.

��ɫ��

��ɫ��